Literature DB >> 8214928

The predictive value of appearances on thin-section computed tomography in fibrosing alveolitis.

A U Wells1, D M Hansell, M B Rubens, P Cullinan, C M Black, R M du Bois.   

Abstract

Fibrosing alveolitis, a condition characterized by a poor prognosis and a limited response to treatment, is readily identified by thin-section computed tomography (CT). Fibrotic and inflammatory histologic results, obtained at open lung biopsy, both have characteristic CT patterns. To evaluate whether CT could predict prognosis and response to therapy, we examined the CT appearances of 76 patients with lone cryptogenic fibrosing alveolitis and 66 patients with fibrosing alveolitis associated with systemic sclerosis. CT abnormalities were categorized as predominantly a ground-glass pattern (Grade 1), mixed (Grade 2), or predominantly a reticular pattern (Grade 3). In cryptogenic fibrosing alveolitis, 4-yr survival was highest in association with CT Grade 1 and higher with CT Grade 2 than with CT Grade 3, independent of the extent of abnormal lung on CT, duration of dyspnea, or severity of depression of DLCO or FVC, p < 0.001. A response to therapy in previously untreated cryptogenic fibrosing alveolitis was seen most frequently with CT Grade 1 and more frequently with CT Grade 2 than with CT Grade 3, p < 0.025. In systemic sclerosis, CT appearances were not predictive of 4-yr survival; a response to therapy was seen more frequently with CT Grade 2 (three of seven patients) than with CT Grade 3 (zero of six patients). These data have shown that CT appearances are of prognostic value in fibrosing alveolitis and that they are likely to play an increasing role in disease-staging in this condition.

Entities:  

Mesh:

Substances:

Year:  1993        PMID: 8214928     DOI: 10.1164/ajrccm/148.4_Pt_1.1076

Source DB:  PubMed          Journal:  Am Rev Respir Dis        ISSN: 0003-0805


  37 in total

Review 1.  Clinical usefulness of high resolution computed tomography in cryptogenic fibrosing alveolitis.

Authors:  A Wells
Journal:  Thorax       Date:  1998-12       Impact factor: 9.139

Review 2.  Lung fibrosis.

Authors:  C Fonseca; D Abraham; C M Black
Journal:  Springer Semin Immunopathol       Date:  1999

Review 3.  Imaging of the pulmonary manifestations of systemic disease.

Authors:  A G Rockall; D Rickards; P J Shaw
Journal:  Postgrad Med J       Date:  2001-10       Impact factor: 2.401

Review 4.  The diagnosis, assessment and treatment of diffuse parenchymal lung disease in adults. Introduction.

Authors: 
Journal:  Thorax       Date:  1999-04       Impact factor: 9.139

Review 5.  Lung involvement in systemic sclerosis.

Authors:  Paul M Hassoun
Journal:  Presse Med       Date:  2010-12-30       Impact factor: 1.228

6.  Acute respiratory distress syndrome mimickers lacking common risk factors of the Berlin definition.

Authors:  Aude Gibelin; Antoine Parrot; Bernard Maitre; Christian Brun-Buisson; Armand Mekontso Dessap; Muriel Fartoukh; Nicolas de Prost
Journal:  Intensive Care Med       Date:  2015-09-25       Impact factor: 17.440

7.  Lung mass density analysis using deep neural network and lung ultrasound surface wave elastography.

Authors:  Boran Zhou; Xiaoming Zhang
Journal:  Ultrasonics       Date:  2018-05-23       Impact factor: 2.890

8.  Lung Ultrasound Surface Wave Elastography: A Pilot Clinical Study.

Authors:  Xiaoming Zhang; Thomas Osborn; Boran Zhou; Duane Meixner; Randall R Kinnick; Brian Bartholmai; James F Greenleaf; Sanjay Kalra
Journal:  IEEE Trans Ultrason Ferroelectr Freq Control       Date:  2017-09       Impact factor: 2.725

Review 9.  Pathogenetic mechanisms in usual interstitial pneumonia/idiopathic pulmonary fibrosis.

Authors:  Eric S White; Michael H Lazar; Victor J Thannickal
Journal:  J Pathol       Date:  2003-11       Impact factor: 7.996

10.  Correlation between pulmonary fibrosis and the lung pressure-volume curve.

Authors:  R H Sansores; A Ramirez-Venegas; R Pérez-Padilla; M Montaño; C Ramos; C Becerril; M Gaxiola; P Paré; M Selman
Journal:  Lung       Date:  1996       Impact factor: 2.584

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.